Usfda Nod

Jump to

Zydus Life arm reports positive phase-3 trial results in rare liver disease, eyes USFDA nod in 2026

The Ahmedabad-based drugmaker plans to file for USFDA approval in the first quarter of 2026, targeting a market projected to reach $10.8 billion by 2026, growing at a CAGR of 36.3%.
Alembic Pharma gets USFDA nod to market heart failure drug

The company has received final approval from the US Food & Drug Administration (USFDA) for Sacubitril and Valsartan Tablets in strengths of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Alembic said in a regulatory filing.
USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert

The USFDA today approved Ranbaxy‘s drug called Plendil generic, which is used for hypertension. Ranbaxy was expected to be the authorised generic for this particular drug, but it is already genericised and there are already 6-7 players in this market for this particular drug.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Usfda Nod

Zydus Life arm reports positive phase-3 trial results in rare liver disease, eyes USFDA nod in 2026

Alembic Pharma gets USFDA nod to market heart failure drug

USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert